U.S. Office of Inspector General Issues Guidance to Health Care Community in Light of Coronavirus Pandemic

3.30.2020

The United States Department of Health and Human Services (HHS), Office of Inspector General (OIG) is a federal agency with a mission to “fight waste, fraud and abuse in Medicare, Medicaid and more than 100 other HHS programs.”  OIG pursues this mission through administrative audits, regulatory and civil enforcement actions, and referrals for criminal prosecution in appropriate cases.

In an extraordinary announcement issued today, OIG provided significant advice to the healthcare community in light of the COVID-19 crisis in two important, but very different areas.

  1. Good-faith Patient Care is Essential

Recognizing that COVID-19 presents new and previously unseen challenges to healthcare providers, OIG advised providers to put good-faith patient care first and foremost on their list of priorities, and not to let doubts or uncertainty about regulatory compliance interfere with patient care:

The delivery of patient care during this public health emergency must be the primary focus of the healthcare industry. . .  For any conduct during this emergency that may be subject to OIG administrative enforcement, OIG will carefully consider the context and intent of the parties when assessing whether to proceed with any enforcement action.

The message – to administer care for the patient as best needed in that moment.  OIG is likely to overlook minor or inadvertent regulatory violations provided those violations were not intentional or motivated by bad faith, and the transgression occurred in the context of the need to provide patient care during this health emergency.  Of course, healthcare providers should take as much care as possible to adhere to regulatory requirements whenever and wherever possible to avoid scrutiny.

  1.  Investigations of Possible Fraud to Increase

The OIG also announced, with abundant clarity, that it would NOT look the other way to avoid taking action in cases of potential fraud. In fact, the OIG said it intends to step up enforcement activity in fraud investigations:  “We are also aggressively investigating bad actors that are exploiting this crisis and preying on people's fears with fraudulent schemes to steal patients' personal information and hawk fake testing kits and unapproved therapies.”

Finally, to the extent that any healthcare providers are in the midst of a regulatory or administrative investigation involving OIG during the pandemic, the agency signaled a willingness to be flexible in terms of scheduling and deadlines.

Those involved in the highly regulated healthcare field should expect OIG to be somewhat flexible during this unprecedented time, but even that flexibility has limits.  Providers are urged to not test the limits, and to focus on reasonable and good-faith efforts to provide the best patient care possible throughout this health crisis.

If you have questions or concerns involving an audit or investigation by the OIG, please contact Darren Gelber, or any member of the Wilentz Criminal Law team.

Tags: Coronavirus (COVID-19)InvestigationsFraudHealthcare

BLOG DISCLAIMER

The postings on this blog were created for general informational purposes only and do not constitute legal advice or a solicitation to provide legal services.  Although we attempt to ensure that the postings are complete, accurate, and current as of the time of publication, we assume no responsibility for their completeness, accuracy, or timeliness.  The information in this blog is not intended to create, and receipt of it does not constitute, a lawyer-client relationship.  Readers should not act upon this information without seeking professional legal counsel.

This blog may contain links to independent third party websites and services, including social media. We provide these links for your convenience, and you access them at your own risk.  We have no control over and do not monitor the content or policies (including privacy policies) of these third-party websites and have no responsibility for, and no liability with respect to, their content, accuracy, or reliability.  Unless expressly stated, we do not endorse any of the linked websites or any product, service, or publication referenced herein or therein.  We will remove a link to any site from this blog upon request of the linked entity.

We grant permission to readers to link to this blog so long as this blog is not misrepresented. This site is not sponsored or associated with any other site unless so identified.

If you wish for Wilentz, Goldman & Spitzer, P.A., to consider representing you, please obtain contact information from the Contact Us area of this blog or go to the firm’s website at www.wilentz.com.  One of our lawyers will be happy to discuss the possibility of representation with you. However, the authors of Wilentz blogs are licensed only in New Jersey and/or New York and do not wish to represent anyone who viewed this site in a state where the site fails to comply with all laws and ethical rules of that state.

Sign Up

Darren M. Gelber Photo

Darren M. Gelber
Chair, Criminal Law Team
Shareholder
732.855.6006